前列腺癌骨转移患者血清差异性相关蛋白质的筛选

Identification of serum protein of prostate cancer with osseous metastasis

目的采用表而增强激光解析电离飞行时间质谱技术筛选前列腺癌骨转移血清差异性相关蛋门质。方法应用美目Ciphergen公司CM10，吕片和蛋白芯片仪检测19例前列腺癌无骨转移患者及35例前列腺癌骨转移患者血清中的蛋白质。利用PBSⅡ—C型蛋白质芯片阅渎仪对CMIO芯片进行检测，所得到的蛋白质以波谱的形式表示。采用BiomarkerWizard软件对2组血清相同质荷比的蛋白质含量数据进行方差分析，导入BiomarkerPattern软件，以得到正确分组的差异性蛋fLI质标志物。结果19例前列腺癌无骨转移患者与35例前列腺癌骨转移患者的血清蛋白质在质荷比为2000～20000时有6个蛋白质含量差异有统计学意义；前列腺癌无骨转移组在质荷比为2089、4281、3507、4178处的蛋白质的相对含量明显高于前列腺癌骨转移组，分别为4．63±8．03和9．88±10．77、19．78±21．46和26．73±19．41、5．46±10．14和8．10±8．74、38．01±26．27和45．25±20．40（P〈0．05）；前列腺癌无骨转移组在质荷比为15900、16081处的蛋白质的相对含量明显低于前列腺癌骨转移组，分别为11．52±16．80和4．84±5．83、8．55±12．64和3．564±3．90（P〈0．05）。结论表面增强激光解析电离飞行时间质谱技术快速、准确，灵敏度、特异度高，通过蛋白芯片仪发现的差异性相关蛋白质，有望成为前列腺癌骨转移诊断中有应用价值的临床柃洲指标．

Objective To identify the biomarkers which can be used of estimating the biological behaviors of prostate cancer with osseous metastasis by SELDI-TOF-MS. Methods Screening for potential tumor biomarkers of senun samples from 19 prostate cancer patients and 35 prostate cancer patients with osseous metastasis by using the technology of SELDI-TOF-MS and CM10 protein chips （Ciphergen Inc. USA）. The PBS Ⅱ protein ehip reader was used to analyze the CM10 protein chips and transform the protein information into the form of spectra. The protein contents of two groups in the same mass-to-charge ratio （M/Z value） were analyzed and preceded the analysis of variance by Biomarker Wizard software. The proteins whose contents in serum were significantly different, which was distinguished the correctly groups by Biomarker Pattern software. Results The contents of 4 proteins in the two groups were significantly different and the M/Z values of these 6 proteins were from 2000 to 20 000. The relative protein content of prostate cancer patients group was higher than that of Prostate Cancer patients with osseous metastasis group at the M/Z value of 2089, 4281, 3507 and 4178 [（4.63±8.03） vs （9.88±10.77）, （19.78±21.46） vs （26.73±19.41）, （5.46±10.14） vs （8.10±8.74）, （38.01±26.27） vs （45.25±20.40）, （P 〈 0.05）]. The relative protein content of prostate cancer patients group was lower than that of prostate cancer patients with osseous metastasis group at the M/Z value of 15 900 and 16 081 [（11.52±16.80） vs （4.84±5.83）, （8.55±12.64） vs （3.56±3.90）, （P〈0.05）]. Conclusion The associated serum protein in prostate cancer with osseous metastasis can be quickly and exactly diagnosed by 5ELDI-TOF-M5 with high sensitivity and specificity. This new method will be widely used in clinical application.